Clinical Trials Logo

Recurrent Renal Cell Cancer clinical trials

View clinical trials related to Recurrent Renal Cell Cancer.

Filter by:

NCT ID: NCT00684996 Terminated - Clinical trials for Renal Cell Carcinoma

Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer

Start date: June 2008
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/randomized phase II trial is studying the side effects and best dose of bevacizumab and to see how well it works when given together with or without MEDI-522 in treating patients with unresectable or metastatic kidney cancer. Monoclonal antibodies, such as bevacizumab and MEDI-522, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab and MEDI-522 may also stop the growth of tumor cells by blocking blood flow to the tumor. It is not yet known whether bevacizumab is more effective when given together with or without MEDI-522 in treating kidney cancer.

NCT ID: NCT00655655 Completed - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors

Start date: December 2004
Phase: Phase 1
Study type: Interventional

RATIONALE: Everolimus and vatalanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving everolimus together with vatalanib may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of everolimus and vatalanib in treating patients with advanced solid tumors.

NCT ID: NCT00408902 Completed - Clinical trials for Clear Cell Renal Cell Carcinoma

Tandutinib in Treating Patients Who Have Undergone Surgery for Metastatic Kidney Cancer

Start date: November 2006
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well tandutinib works in treating patients who have undergone surgery for metastatic kidney cancer. Tandutinib may stop the growth of kidney cancer by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving tandutinib after surgery may kill any tumor cells that remain after surgery.

NCT ID: NCT00354250 Completed - Clinical trials for Stage IV Renal Cell Cancer

Ispinesib in Treating Patients With Metastatic or Unresectable Kidney Cancer

Start date: May 2006
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well ispinesib works in treating patients with metastatic or unresectable kidney cancer. Ispinesib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT00348699 Completed - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

AFP464 in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery

Start date: July 2006
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of AFP464 in treating patients with metastatic or refractory solid tumors that cannot be removed by surgery. Drugs used in chemotherapy, such as AFP464, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

NCT ID: NCT00324870 Completed - Clinical trials for Clear Cell Renal Cell Carcinoma

Vorinostat and Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer

Start date: February 2006
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial is studying the side effects and best dose of vorinostat when given together with bevacizumab and to see how well they work in treating patients with unresectable or metastatic kidney cancer. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of kidney cancer by blocking blood flow to the tumor. Giving vorinostat together with bevacizumab may kill more tumor cells.

NCT ID: NCT00324740 Terminated - Clinical trials for Stage IV Renal Cell Cancer

Vorinostat and Isotretinoin in Treating Patients With Advanced Kidney Cancer

Start date: March 2006
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial is studying the side effects and best dose of isotretinoin when given together with vorinostat and to see how well they work in treating patients with advanced kidney cancer. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Isotretinoin may cause kidney cancer cells to look more like normal cells, and to grow and spread more slowly. Giving vorinostat together with isotretinoin may kill more tumor cells.

NCT ID: NCT00303862 Terminated - Clinical trials for Clear Cell Renal Cell Carcinoma

AZD2171 in Treating Patients With Refractory Metastatic Kidney Cancer

Start date: March 2006
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well AZD2171 works in treating patients with refractory metastatic kidney cancer. AZD2171 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

NCT ID: NCT00217542 Completed - Recurrent Melanoma Clinical Trials

Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By Surgery

Start date: July 2005
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of recombinant interferon alfa-2b when given together with azacitidine in treating patients with stage III or stage IV melanoma or stage IV kidney cancer that cannot be removed by surgery. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Recombinant interferon alfa-2b may interfere with the growth of tumor cells. Giving azacitidine together with recombinant interferon alfa-2b may kill more tumor cells.

NCT ID: NCT00182702 Completed - Clinical trials for Clear Cell Renal Cell Carcinoma

Ixabepilone in Treating Patients With Metastatic, Recurrent, or Unresectable Kidney Cancer

Start date: July 2005
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well ixabepilone works in treating patients with metastatic, recurrent, or unresectable kidney cancer. Drugs used in chemotherapy, such as ixabepilone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing